Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Sell
18
MCRB Quote, Financials, Valuation and Earnings
Last price:
$14.97
Seasonality move
:
-11.78%
Day range:
$14.49 - $15.25
52-week range:
$6.53 - $29.98
Dividend yield:
0%
P/E ratio:
24.71x
P/S ratio:
372.65x
P/B ratio:
3.01x
Volume:
52.3K
Avg. volume:
246.6K
1-year change:
-22.29%
Market cap:
$131.3M
Revenue:
--
EPS (TTM):
$0.61
Analysts' Opinion
-
Consensus RatingSeres Therapeutics, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $21.00, Seres Therapeutics, Inc. has an estimated upside of 40% from its current price of $15.00.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $20.00 representing 100% downside risk from its current price of $15.00.
Fair Value
-
According to the consensus of 3 analysts, Seres Therapeutics, Inc. has 40% upside to fair value with a price target of $21.00 per share.
MCRB vs. S&P 500
-
Over the past 5 trading days, Seres Therapeutics, Inc. has underperformed the S&P 500 by -9.22% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Seres Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Seres Therapeutics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Seres Therapeutics, Inc. reported revenues of $351K.
Earnings Growth
-
Seres Therapeutics, Inc. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter Seres Therapeutics, Inc. reported earnings per share of $0.94.
Enterprise value:
168.9M
EV / Invested capital:
1.31x
Price / LTM sales:
372.65x
EV / EBIT:
6.02x
EV / Revenue:
481.29x
PEG ratio (5yr expected):
-0.07x
EV / Free cash flow:
-7.23x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
4.82x
Gross Profit (TTM):
-$5.9M
Return On Assets:
3.5%
Net Income Margin (TTM):
--
Return On Equity:
16.36%
Return On Invested Capital:
4.41%
Operating Margin:
-6403.7%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $126.9M | -- | $351K | -- | $351K | |
| Gross Profit | $114.8M | -$14.9M | -$5.9M | -$1.4M | -$693K | |
| Operating Income | -$127.6M | -$129.5M | -$103.4M | -$29.2M | -$22.5M | |
| EBITDA | -$115.4M | -$114.6M | -$97.2M | -$27.8M | -$21.4M | |
| Diluted EPS | -$8.22 | -$16.59 | $0.61 | -$0.38 | $0.94 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $358.8M | $247.5M | $214.4M | $72.9M | $51.5M | |
| Total Assets | $396.3M | $311.9M | $367.7M | $178.7M | $143.5M | |
| Current Liabilities | $94.6M | $81.8M | $79.2M | $64.8M | $22.4M | |
| Total Liabilities | $220.6M | $244.3M | $382.8M | $154.8M | $99.8M | |
| Total Equity | $175.7M | $67.6M | -$15.1M | $23.9M | $43.7M | |
| Total Debt | $37.7M | $68.7M | $206M | $85.3M | $75.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$122.7M | -$157.2M | -$23.1M | -$34.7M | $2.2M | |
| Cash From Investing | $17.4M | $141.5M | -$313K | $141.1M | -$8K | |
| Cash From Financing | $69.9M | -$85.7M | $3M | -$110.9M | $61K | |
| Free Cash Flow | -$133.3M | -$158.4M | -$23.4M | -$34.8M | $2.2M | |
MCRB
Sector
Market Cap
$131.3M
$28.1M
Price % of 52-Week High
50.03%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
13.36%
-1.49%
1-Year Price Total Return
-22.29%
-17.13%
Beta (5-Year)
0.182
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$15.55
200-day SMA
Buy
Level
$14.12
Bollinger Bands (100)
Sell
Level
15.25 - 20.01
Chaikin Money Flow
Sell
Level
-17.1M
20-day SMA
Sell
Level
$16.51
Relative Strength Index (RSI14)
Sell
Level
41.65
ADX Line
Sell
Level
16.09
Williams %R
Neutral
Level
-74.9354
50-day SMA
Sell
Level
$17.23
MACD (12, 26)
Sell
Level
-0.75
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Sell
Level
-295.5K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-11.918)
Sell
CA Score
(Annual)
Level (-5.1833)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (7.0662)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
Stock Forecast FAQ
In the current month, MCRB has received 1 Buy ratings 2 Hold ratings, and 0 Sell ratings. The MCRB average analyst price target in the past 3 months is $21.00.
-
Where Will Seres Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Seres Therapeutics, Inc. share price will rise to $21.00 per share over the next 12 months.
-
What Do Analysts Say About Seres Therapeutics, Inc.?
Analysts are divided on their view about Seres Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Seres Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $20.00.
-
What Is Seres Therapeutics, Inc.'s Price Target?
The price target for Seres Therapeutics, Inc. over the next 1-year time period is forecast to be $21.00 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is MCRB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Seres Therapeutics, Inc. is a Hold. 2 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of MCRB?
You can purchase shares of Seres Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Seres Therapeutics, Inc. shares.
-
What Is The Seres Therapeutics, Inc. Share Price Today?
Seres Therapeutics, Inc. was last trading at $14.97 per share. This represents the most recent stock quote for Seres Therapeutics, Inc.. Yesterday, Seres Therapeutics, Inc. closed at $15.00 per share.
-
How To Buy Seres Therapeutics, Inc. Stock Online?
In order to purchase Seres Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get MCRB Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MCRB
Sector
P/E ratio
24.71x
23.89x
PEG ratio
-0.07x
-0.01x
P/B ratio
3.01x
1.81x
Price / LTM sales
372.65x
1.59x
Growth Metrics
MCRB
Sector
Revenue growth
--
4.62%
Earnings growth
346.46%
11.06%
Revenue (5-year growth)
-100%
6.5%
Earnings forecast
$1.28
-$0.21
Profitability
MCRB
Sector
Profitability FY 2024
-$14.7M
$3.6M
Return on invested capital
4.41%
-31.84%
Return on assets
3.5%
-27.96%
Return on equity
16.36%
-37.63%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Mar
12
Estimated Next Earnings Date
Feb
4
Balance Sheet
MCRB
Sector
Total cash
$47.6M
$26.4M
Short term investments
--
$25.7M
Total assets
$139.8M
$76.9M
Long term debt
$75.3M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 3.24% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 1.39% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
